A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|20|3639-3648

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.20, 2015-10, pp. : 3639-3648

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 214-220

Karger

Access to resources Recommend Favorite

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 446-453

Karger

Access to resources Recommend Favorite

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 372-383

Karger

Access to resources Recommend Favorite

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 648-655

Karger

Access to resources Recommend Favorite